ELISA
Biovica Inks Master Service Agreement for Oncology-Use Cell Proliferation Assay
The firm's DiviTum TKa assay will be used in drug development studies, and the firm said the deal could lead to the development of the test as a companion diagnostic.
OncoHost Raises $35M in Series C Financing
The Israeli firm will use the funds to expand its PROPHETIC trial and support the US commercial launch of the Prophet platform.
Israeli Startup OncoHost Eyeing 2022 Commercial Launch of Immunotherapy Response Prediction Test
Premium
The firm is validating its proteomics- and machine learning-based Prophet platform and setting up US operations in anticipation of a commercial launch next year.
The Swedish firm Biovica said this and additional studies will form the basis of a US Food and Drug Administration submission for its test measuring thymidine kinase-1.